Q-omics provides the consensus-scored GALNT5 profile across patient tissues and cancer cell-line models. GALNT5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, GALNT5 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, GALNT5 RNA expression shows 20,983 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, HNSC, and GBM as cancer lineages where GALNT5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT5 survival associations across molecular data types. GALNT5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT5 RNA expression–survival associations across cancer types. High GALNT5 expression shows unfavorable associations in LGG, MESO, KICH and BLCA, but favorable associations in READ and HNSC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for GALNT5 RNA expression.
This table summarizes GALNT5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GALNT5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT5 shows lower tumor expression in HNSC and LUSC and higher tumor expression in THCA, KIRP, BRCA and UCEC. The HNSC box plot shows higher GALNT5 RNA expression in normal versus tumor tissue (log2 FC = −1.145, t-test p = .001).
This table shows molecular features associated with GALNT5 in patient tissues and cancer cell lines. In patient samples, GALNT5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
